ReWalk Robotics

98 articles with ReWalk Robotics

• ReWalk Robotics Reports Third Quarter 2021 Financial Results

  11/10/2021

  ReWalk Robotics Ltd. (Nasdaq: RWLK) (“ReWalk” or the “Company”) today announced its financial results for the three and nine months ended September 30, 2021.

• ReWalk Robotics to Hold its Third Quarter 2021 Earnings Call on November 11, 2021

  11/5/2021

  ReWalk Robotics Ltd. (Nasdaq: RWLK) (“ReWalk” or the “Company”) today announced that management will hold its third quarter 2021 earnings call Thursday, November 11, 2021, at 8:30 AM Eastern time. 

• FDA Awards Breakthrough Device Designation to the ReWalk ReBoot Soft Exo-Suit

  11/4/2021

  ReWalk Robotics, Ltd.  today announced its ReBoot device has been granted designation as a Breakthrough Device by the Food and Drug Administration (FDA).

• ReWalk Robotics Announces $32.5 Million Registered Direct Offering Priced At Premium to Market

  9/27/2021

  ReWalk Robotics Ltd. (Nasdaq: RWLK) (“ReWalk” or the “Company”) today announced that it has entered into definitive agreements with several institutional investors providing for the issuance of 16,013,518 of the Company’s ordinary shares (or ordinary share equivalents in lieu thereof), at an effective purchase price of $2.035, in a registered direct offering priced at-the-market under Nasdaq Rules.

• ReWalk Robotics Reports Second Quarter 2021 Financial Results

  8/9/2021

  ReWalk Robotics Ltd. announced its financial results for the three and six months ended June 30, 2021.

• ReWalk Robotics Appoints Senior Biotech Executive, Jeannine Lynch, as Vice President of Strategy and Market AccessMs. Lynch will lead ongoing building and implementation of ReWalk’s market access and reimbursement programs

  8/2/2021

  ReWalk Robotics Ltd.  today announced Jeannine Lynch will join the Company on August 31, 2021, as Vice President of Strategy and Market Access.

• ReWalk Robotics Reports First Quarter 2021 Financial Results

  5/11/2021

  ReWalk Robotics Ltd. (Nasdaq: RWLK) (“ReWalk” or the “Company”) today announced its financial results for the three months ended March 31, 2021. Highlights of and subsequent to the first quarter of 2021 include: The Company’s total revenue in the first quarter of 2021

• ReWalk Robotics to Present at the H.C. WAINWRIGHT Global Life Sciences Virtual Conference

  3/4/2021

  ReWalk Robotics Ltd. announced that Larry Jasinski, Chief Executive Officer and Ori Gon, Chief Financial Officer will present at H.C.WAINWRIGHT global life science conference held on March 9 – 10, 2021.

• National Institute for Health and Care Excellence (NICE) Publishes Briefing on ReStore Soft Exo-Suit in the UK

  3/3/2021

  Experts outline potential for improved stroke patient outcomes, cost effectiveness through use of the ReStore device in the rehabilitation setting

• ReWalk Enters Contract with BKK Mobil Oil health insurance fund for the supply of ReWalk exoskeleton to eligible persons with spinal cord injury in Germany

  3/2/2021

  ReWalk Robotics, Ltd., a leading manufacturer of robotic medical devices for people with lower extremity disabilities, announced it has entered into a contract with BKK Mobil Oil Insurance to provide ReWalk Personal Exoskeleton devices to its eligible beneficiaries with spinal cord injury.

• ReWalk Robotics Announces Closing of $40.0 Million Private Placement Priced At-the-Market

  2/26/2021

  ReWalk Robotics Ltd. (Nasdaq: RWLK) (“ReWalk” or the “Company”) today announced the closing of its previously announced private placement of 10,921,502 ordinary shares and warrants to purchase up to 5,460,751 ordinary shares, at a purchase price of $3.6625 per share and associated warrant, that was priced “at-the-market” under Nasdaq rules and resulted in gross proceeds of approximately $40.0 million

• ReWalk Robotics Announces $40.0 Million Private Placement Priced At-the-Market

  2/19/2021

  ReWalk Robotics Ltd. (Nasdaq: RWLK) (“ReWalk” or the “Company”) today announced that it has entered into securities purchase agreements with certain institutional and other accredited investors to raise $40.0 million through the issuance of 10,921,502 ordinary shares and warrants to purchase up to 5,460,751 ordinary shares,

• ReWalk Robotics Reports Fourth Quarter and Year End 2020 Financial Results

  2/18/2021

  Continued CMS progress made with issuance of HCPCS Level II Code for ReWalk Exoskeleton enabling an upcoming application for coverage

• ReWalk Robotics to Report Fourth Quarter 2020 Financial Results on February 18, 2021

  2/15/2021

  ReWalk Robotics Ltd. (Nasdaq: RWLK) (“ReWalk” or the “Company”) today announced that the Company will release its fourth quarter 2020 financial results on Thursday, February 18, 2021, before the U.S. financial markets open.    Larry Jasinski, Chief Executive Officer, and Ori Gon, Chief Financial Officer, will host a conference call to discuss the results as follows: Time 8:30 A.M EST Tol

• ReWalk Robotics Repays Outstanding Balance on Kreos Credit Line

  1/6/2021

  ReWalk Robotics Ltd. announced that it has repaid in full the outstanding balance on its credit line from Kreos Capital V Limited.

• ReWalk Robotics Donates ReStore Exo-Suit to Brooks Rehabilitation to Support Stroke Survivors

  12/21/2020

   ReWalk Robotics, Ltd. (Nasdaq: RWLK) ("ReWalk" or the "Company"), a manufacturer of robotic medical devices for individuals with lower limb disabilities, today announced it has donated one of its ReStore Exo-suits t

• Leading German Private Health Insurer Enters Contract to Provide ReWalk Exoskeletons to Individuals with Spinal Cord Injuries

  12/10/2020

  ReWalk Robotics, Ltd., a leading manufacturer of robotic medical devices for people with lower extremity disabilities, announced it has entered into a contract with a German private health insurance company to allow all eligible beneficiaries with spinal cord injury to apply for the procurement of a ReWalk 6.0 exoskeleton system.

• ReWalk Robotics Announces Closing of $8.0 Million Private Placement Priced At-the-Market

  12/8/2020

  ReWalk Robotics Ltd., announced the closing of its previously announced private placement of 5,579,776 ordinary shares and warrants to purchase up to 4,184,832 ordinary shares, at a purchase price of $1.43375 per share and associated warrant, that was priced “at-the-market” under Nasdaq Rules and resulted in gross proceeds of approximately $8.0 million before the deduction of placement agent fees and expenses and estimated offering expenses payable by the Company.

• ReWalk Robotics Announces $8.0 Million Private Placement Priced At-the-Market

  12/3/2020

  ReWalk Robotics Ltd. (Nasdaq: RWLK) (“ReWalk” or the “Company”), today announced that it has entered into securities purchase agreements with certain institutional and other accredited investors to raise $8.0 million through the issuance of 5,579,776 its ordinary shares and warrants to purchase up to 4,184,832 ordinary shares, at a purchase price of $1.43375 per share and associated warrant, in a private

• ReWalk Robotics Reports Third Quarter 2020 Financial Results

  11/10/2020

  ReWalk Robotics Ltd. announced its financial results for the three and nine months ended September 30, 2020.